Two major nurses associations are applauding the Trump administration’s move to federally reschedule marijuana, which they say will pave the path for expanded research into the potential health benefits of cannabis if the rule is finalized.
After President Donald Trump signed an executive order this month directing the attorney general to complete the process of moving marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA), the American Nurses Association (ANA) and the American Association of Nurse Anesthesiology (AANA) put out statements commending the action.
“Rescheduling cannabis to Schedule III advances public health by expanding access to rigorous research, supporting evidence-informed clinical care, and reinforcing patient safety through regulated study and oversight,” ANA—which also cheered the initial reclassification recommendation from the U.S. Department of Health and Human Services (HHS) under the Biden administration—said.
“ANA supports the President’s executive order rescheduling cannabis from a Schedule I to a Schedule III substance under the Controlled Substances Act,” it said. “This action reflects scientific review and acknowledges evidence demonstrating that cannabis has accepted medical use and a safety profile consistent with Schedule III classification.”
The modest reform provides “clearer alignment between federal policy and medical practice,” which in turn “supports
Read full article on Marijuana Moment
